An observational study in Autism Spectrum Disorder, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Autistic Disorder with a site in France — 10 open to participants now, 10 under way, 1 of them phase 3. Autistic Disorder · France.
Among the 50 studies in Autistic Disorder with a site in France, this one is the 11th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2025, is one of 13 observational ones, and was the 44th registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →10 of the 50 studies in Autistic Disorder with a site in France are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in France, United States, Australia and 8 more countries
Ages 5–17
University Hospital, Brest · Sites in France
Ages up to 24
Centre Hospitalier Intercommunal Robert Ballanger · Sites in France
Ages 3–15
University Hospital, Tours · Sites in France
Ages 18+ · Healthy volunteers
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 24 mo–70 yrs · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 102 across 191 observational studies indexed under Autistic Disorder.
Median enrollment 60 across the 37 interventional studies, 103 across the 13 observational. Of the 32 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 50 have an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 1 study filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Autistic Disorder with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06443320Centre Hospitalier Intercommunal Robert BallangerEvaluation of the Videodrama Therapeutic Device for Children with Autism Spectrum Disorders | 2027-03-04 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies in Autistic Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to compare the neural correlates of predictive brain mechanisms during high-level social and non-social flexibility tasks, between autistic and non-autistic males and females. The aim is to better understand if autistic individuals differ from non-autistic individuals in their cognitive flexibility according to the social and predictable nature of the stimuli, at a behavioral and neurofunctional level using the functional Magnetic Resonance Imaging (fMRI). As autistic females usually present a more subtle profile than autistic males, the investigators will also explore if autistic males and females present neurofunctional differences.
Background:
Autism spectrum conditions (ASC) may involve specificities in predictive brain mechanisms, which guide perception together with sensory input. These predictive mechanisms are at play in various aspects of life, such as social interactions, in which autistic individuals have difficulties. They are also important for cognitive flexibility, which involves changing tasks, strategies, or perspectives according to the situation. recent research highlighted that autistic individuals faced difficulties in flexibly adjusting their predictions to unpredictable social contexts during a socio-emotional flexibility task (social stimuli). However, they found no difference between autistic and non-autistic individuals during a cognitive flexibility task involving predictable changes of non-social stimuli. This study aims to more precisely investigate which conditions lead to flexibility difficulties in autism (i.e., the social context, the unpredictability, or both) and to investigate the brain networks involved in autistic and non-autistic participants during high-level cognitive flexibility tasks involving social and non-social stimuli. In addition, autistic females often presenting better socio-communicational abilities than autistic males and a different profile from males in past research involving cognitive flexibility, the investigators will explore if they present a different neurofunctional signature from males during these tasks.
Procedure:
The protocol begins with an imaging localization phase (5 minutes). Subsequently, functional MRI tasks (T2*) commence. The protocol consists of two cognitive tasks, performed within the MRI scanner, each preceded by a training phase. The acquisition of each participant's anatomical sequence (T1; 5 minutes) is conducted between the first two cognitive tasks to avoid compromising participant concentration. Finally, functional connectivity data are collected during a 'resting state' sequence (10 minutes). The study comprises a single visit.
Cognitive Tasks:
The protocol starts with an Emotional Shifting Task (EST), where participants evaluate the valence of emotion (positive vs. negative) on an image while it's truncated; then, the image appears not truncated, and the participant must reevaluate its valence. In some cases, the valence has changed (from positive to negative or from negative to positive), and the participant must consider scene cues and demonstrate flexibility to reassess their judgment. This task lasts approximately 11 minutes.
In a second group of tasks, the participant will perform adapted versions of the Task-Switching Task (TST). In the first task, a letter and a number appear side by side, surrounded by either a blue or yellow frame. When the stimulus appears in a blue frame, the participant must focus on the letter and press the left response button if it's a consonant and the right response button if it's a vowel. When the stimulus appears in a yellow frame, the participant must focus on the numbers and press the left response button when it's odd and the right response button when it's even. In the first part, the subject first practices only the letter task to assimilate the task. Then, similarly, the subject practices only the number task. Finally, the subject performs the alternating task, with 2 conditions of predictability: predictable (task change every three trials), and not predictable (random change). This task lasts approximately 10 minutes. The second task adds an emotional component to the TST task: a face (male or female) associated with an emotion (positive or negative) is surrounded by either a blue or yellow frame. When the stimulus appears in a blue frame, the subject must focus on the gender and press the right response button if it's a female and the left response button if it's a male. When the stimulus appears in a yellow frame, the subject must focus on the facial emotion and press the right response button if it's a positive facial emotion and the left response button if it's a negative facial emotion. In the first part, the subject first practices only the gender task to assimilate the task. Then, similarly, the subject practices only the emotional task. Finally, the subject performs the alternating task, with the 2 conditions of predictability. This task also lasts 10 minutes.
Psychometric Assessment :
The subject will also undergo a psychometric assessment including the Social Responsiveness Scale (SRS), Camouflaging Autistic Trait - questionnaire (CAT-Q), Weschler Adult Intelligence Scale 4th edition (WAIS-4), Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A), Empathy Quotient (EQ), Autism Spectrum Quotient (AQ), and Autism Diagnostic Interview -revised (ADI-R) with the parent (if possible).
Hypotheses:
Given the literature, the investigators hypothesize a reduction in activation of certain areas in predictable conditions compared to unpredictable conditions, indicating the presence of a prediction error. Specifically, in the socio-emotional flexibility task (EST), the investigators expect to observe this reduction, particularly in the precuneus, the temporal lobe, the fusiform gyrus, and the locus coeruleus. In the cognitive flexibility task (adapted TST), the investigators will more specifically focus on the locus coeruleus. The investigators also anticipate observing the involvement of a global functional network showing differences in activations between autistic and non-autistic individuals, as well as a modulation of this reduction in activation (prediction error) between the two groups. Finally, the investigators hypothesize an intermediate profile in autistic females, both at the behavioral and neurofunctional level, situated between those of autistic males and non-autistic females.
Data Analysis:
Behavioral data will be analyzed in terms of accuracy rates and reaction times for both tasks. fMRI data will undergo classical analysis (General Linear Model - GLM). This GLM analysis will allow a direct comparison of experimental conditions within the same group of participants and identify possible differences in activations between the groups.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
This study's planned enrollment of 40 is below the median of 102 across 191 observational studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Autistic with a diagnosis and non autistic adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For non autistic individuals
For autistic individuals:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have an autism diagnosis.
Behavioral: Social/non social; predictable vs unpredictable
Participants who do not have an autism diagnosis
Behavioral: Social/non social; predictable vs unpredictable
Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)
Neurofunctional activity specificity of autistic adults in predictive processes during cognitive flexibility tasks
fMRI BOLD signal
Time frame: during activation tasks
Functional connectivity specificity of autistic adults
BOLD-fMRI signal during resting state (BOLD-RS)
Time frame: through study completion, an average of 1 year
EST accuracy
the emotional shifting task (EST), is one of the task that will be performed in the fMRI. During this task participants evaluate the valence of emotion (positive vs. negative) on an image while it's truncated; then, the image appears not truncated, and the participant must reevaluate its valence. In some cases, the valence has changed (from positive to negative or from negative to positive), and the participant must consider scene cues and demonstrate flexibility to reassess their judgment. We will collect the accuracy of this task
Time frame: through study completion, an average of 1 year
EST response time
We will collect the response time in this task (described above)
Time frame: through study completion, an average of 1 year
TST accuracy
The Task-Switching Task (TST) is described in the study description. We will collect the accuracy of this task
Time frame: through study completion, an average of 1 year
TST response time
We will collect the response time in this task (described above)
Time frame: through study completion, an average of 1 year
SRS
The social responssivness scale is a scale giving a score between 0 and 195, that help to identify social difficulties in autism. Higher values indicate greater expression of the ASD-related phenotype. The self reported-version will be used.
Time frame: through study completion, an average of 1 year
AQ
The Autism spectrum quotient is a self-administrated questionnaire, with scores ranging from 0 to 50, that helps to identify autistic traits. Higher values indicate greater expression of the ASD-related phenotype
Time frame: through study completion, an average of 1 year
EQ
The empathy quotient is a self-administrated questionnaire, with scores ranging from 0 to 80. Higher values indicate high ability to understand how other people feel
Time frame: through study completion, an average of 1 year
CAT-Q
The Camouflaging Autistic Trait Questionnaire (CAT-Q) is a self-administered questionnaire, with scores ranging from 25 to 75. Higher values indicate greater camouflaging, i.e., greater ability to mask autistic symptoms in social contexts.
Time frame: through study completion, an average of 1 year
BRIEF-A
The Behavior Rating Inventory of Executive Function-Adult Version ( BRIEF-A) is a self-administrated questionnaire measuring executive dysfunctions. The global raw score can range from 70 to 210. Higher scores indicate greater executive dysfunctions
Time frame: through study completion, an average of 1 year
WAIS-IV
The Weschler Adult Intelligence Scale 4th edition (WAIS-IV) measure IQ. Higher scores indicate a higher Intelligence Quotient - IQ)
Time frame: through study completion, an average of 1 year
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Apr 2029, 49 months after the start.
Of 57 non-industry observational studies under Autistic Disorder, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 49 months is below that.
Counting every sponsor, half of 65 studies reached it within 43 months; a quarter within 20 and three quarters within 120.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Jun 2024 → Feb 2025, primary completion Dec 2026 → Apr 2029 and completion Dec 2028 → Apr 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →